Recently, amplification of Mcl-1 gene loci was also found in triple-negative breast cancer, and NOXA, an endogenous Mcl-1 inhibitor, depressed HER2-positive breast cancers, suggesting that DRB could be further explored as treatment strategies for ER-negative breast cancer18,50. The gene discussed is MCL1; the disease is triple-negative breast carcinoma.